Pelthos Therapeutics initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage of Pelthos Therapeutics (PTHS) with an Overweight rating and $50 price target Pelthos is emerging as a commercial launch story, with early script trends indicating growing traction in a large, under-penetrated market, the analyst tells investors in a research note. The current valuation appears disconnected from this progress, as the opportunity centers on scaling an already approved product rather than clinical-stage binary outcomes, the firm adds.